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Both oxidative stress and mast cell (MC) degranulation participate in the process of small intestinal ischemia reperfusion (IIR)
injury, and oxidative stress induces MC degranulation. Propofol, an anesthetic with antioxidant property, can attenuate IIR injury.
We postulated that propofol can protect against IIR injury by inhibiting oxidative stress subsequent fromNADPHoxidasemediated
MC activation. Cultured RBL-2H3 cells were pretreated with antioxidant N-acetylcysteine (NAC) or propofol and subjected to
hydrogen peroxide (H
2
O
2
) stimulation without or with MC degranulator compound 48/80 (CP). H
2
O
2
significantly increased
cells degranulation, which was abolished by NAC or propofol. MC degranulation by CP further aggravated H
2
O
2
induced cell
degranulation of small intestinal epithelial cell, IEC-6 cells, stimulated by tryptase. Rats subjected to IIR showed significant increases
in cellular injury and elevations of NADPH oxidase subunits p47phox and gp91phox protein expression, increases of the specific
lipid peroxidation product 15-F
2t-Isoprostane and interleukin-6, and reductions in superoxide dismutase activity with concomitant
enhancements in tryptase and 𝛽-hexosaminidase. MC degranulation by CP further aggravated IIR injury. And all these changes
were attenuated by NAC or propofol pretreatment, which also abrogated CP-mediated exacerbation of IIR injury. It is concluded
that pretreatment of propofol confers protection against IIR injury by suppressing NADPH oxidase mediated MC activation.
1. Introduction
Small intestinal ischemia reperfusion (IIR) injury has been
emerged in many pathophysiological settings, including sep-
tic and hemorrhagic shock induced hypoperfusion [1], as
well as acute mesenteric ischemia [2] and small intestine
transplantation or liver resection [3]. IIR remains to be a
critical problem associated with high mortality [4].
During IIR, oxidative stress is increased due to burst
production of reactive oxygen species (ROS),which is amajor
mechanism of IIR injury [5]. Numerous studies have revealed
that increased ROS production resulted from overactivation
of the prooxidant enzyme NADPH oxidase, which abun-
dantly exists in intestine tissue [6] and plays critical roles in
mediating tissue injury related to a range of inflammatory
diseases [7], including ischemia reperfusion injury [8, 9].
Inhibition of NADPH oxidase by N-acetylcysteine (NAC),
a scavenger of oxygen radicals, has been shown to greatly
attenuate myocardial ischemia reperfusion injury [10, 11].
However, the mechanism governing ROS production, specif-
ically, from overactivation of NADPH oxidase, during IIR is
yet to be explored.
Activation of NADPHoxidase can lead tomast cells (MC,
cells that widely present throughout small intestine) degran-
ulation/activation [12], wherever MCs activation has been
demonstrated to be a key mediator in the pathogenesis of IIR
and contributing to many disorders as a result of increased
release a diverse range of mediators including histamine,
tryptase, and inflammatory cytokines such as interleukin-6
(IL-6) [13] and that inhibition of MCs from degranulation
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can alleviate IIR injury [14, 15]. We have previously found
that ROS production was significantly increased after IIR
which is parallel with the enhancements inMCdegranulation
[16], but it is unknown whether a causal relationship exists
between increased ROS production and MC degranulation
in the setting of IIR in vivo. These findings [6, 17] together
with reports showing that MC can be activated in a ROS-
dependent pathway [18], both in vitro [18] and in vivo [16],
prompted us to postulate that during IIR increased ROS
production initiates and/or exacerbates IIR injury primarily
via activating MC and that NADPH oxidase activation is
increased during IIR which may be a major source of ROS
overproduction during IIR.
Propofol, an intravenous anesthetic with antioxidant
property that we widely used in intensive care unit and
operation theatre, has been shown to dose-dependently
attenuate myocardial ischemia reperfusion injury in patients
[19]. Propofol has also been shown to inhibit mast cell
exocytosis in a dose-dependent manner in vitro [20]. A most
recent study shows that propofol attenuates brain trauma
induced cerebral injury through inhibiting NADPH oxidase
activation [21]. We, therefore, hypothesized that inhibition of
ROS mediated MC activation subsequent to attenuation of
intestinal NADPH oxidase activation may represent a major
mechanism by which propofol attenuates IIR injury. This
hypothesis was tested in a rat model of mesenteric ischemia
reperfusion in vivo and a rat cell line of mast cell exposed to
ROS in vitro.
2. Materials and Methods
2.1. Cell Culture. Ratmast cell line (RBL-2H3) was purchased
from the cell bank of the Chinese Academy of Sciences
(Shanghai, China) and was cultured in Eagle’s minimum
essential medium containing 10% fetal bovine serum, sup-
plemented with 100U/mL penicillin and 100 𝜇g/mL strep-
tomycin at 37∘C in a humidified atmosphere of 5% CO
2
as described [22]. A rat small intestinal epithelial cell line
(IEC-6) was also obtained from the cell bank of the Chinese
Academy of Sciences (Shanghai, China). This cell line was
cultured in 1640 RPMI medium with 10% fetal bovine serum
at 37∘C in a 5% CO
2
incubator.
2.2. Measurement of Cell Degranulation. Degranulation of
RBL-2H3 cells was measured by determining the activity
of released 𝛽-hexosaminidase in the culture supernatants
and cell lysates [23]. The RBL-2H3 cells were incubated
with different concentrations of NAC [24] or propofol [20]
for 12 h; after the cells were washed with 1 × PBS for 3
times, RBL-2H3 cells were incubated in a 24-well plate (1 ×
106 cells/well) at 37∘C overnight.The above cells were washed
with 1×PBS and then incubatedwith different concentrations
of lipopolysaccharides (LPS) [25] or H
2
O
2
[26] or Com-
pound 48/80 [27] for 1 h or 4 h. To measure the amount of
𝛽-hexosaminidase activity released from the cells, the cul-
tured media were transferred and centrifuged at 4∘C. The
supernatant (25 𝜇L) was mixed with 50𝜇L p-NAG (10mM)
in 0.1M sodium citrate buffer (pH 4.5) into a 96-well plate
and incubated for 1 h at 37∘C.The reaction was terminated by
the addition of stop buffer (0.1M sodium carbonate buffer,
pH 10.0). The 𝛽-hexosaminidase activity was determined
by measuring the difference of absorbance at wavelength
405 nm.
2.3. Measurement of Cell Viability. IEC-6 cells were seeded
into 96-well flat bottom culture plates at a density of 5 ×
104 cells/well and incubated for 24 h. After exposure to
tryptase (0–1000 ng/mL) for 12 h in RPMI 1640 culture
medium, the cell viability was measured by modified MTT
assay as described [28]. The assay detected the reduction of
the tetrazolium to formazan product. The cell viability was
evaluated using the following formula. Survival rate (%) =
(𝐴 sample – 𝐴blank)/(𝐴control – 𝐴blank) × 100%.
2.4. Assessment of Cell Cytotoxicity. Cytotoxicity (cell necro-
sis) was assessed by measuring the release of lactate dehy-
drogenase (LDH). After exposure of the cells to various con-
centrations of tryptase (0–1000 ng/mL) for 2 h in RPMI 1640
culture medium, cell necrosis was assessed by LDH-release
assay using a commercial kit (Jiancheng, China) according to
the manufacturer’s instruction.
2.5. Animals. Female Sprague-Dawley (SD) rats weighing
180–200 g, purchased from Animal Center of Guangdong
Province (Guangzhou, China), were housed individually in
wire-bottomed cages and were placed under pathogen free
condition illuminated from 8:00 AM to 8:00 PM (12:12 h
light-dark cycle) for one week before use. The experimental
protocol and design was approved by the Sun Yat-sen Uni-
versity Animal Experimentation Committee and performed
according to Sun Yat-sen University Guidelines for Animal
Experimentation.
2.6. In Vivo Rat IIR Model and Treatments. All the ani
mals were fasted for 16 h (while free access to water was
allowed) before surgery. Rats were, respectively, injected
withN-acetylcysteine (NAC, 0.5 g/kg, from Sigma company),
propofol (50mg/kg, commercial product Diprivan from
AstraZeneca), intralipid (50mg/kg, 20%, emulsion from
Sigma), or normal saline (0.5mL/100 g), which served as the
control group, intraperitoneally at 6:00 PM for 3 successive
days. The dosages of NAC were chosen based on the results
showing that treatment of rats with i.p. NAC (500mg kg−1
per day for 9 days) improved the renal hemodynamic changes
triggered by cisplatin-mediated nephrotoxicity [29].The dose
of propofol was chosen based on the finding that propofol
50mg/kg given intraperitoneally provided sedative effect but
not anesthetic effect [30] and that propofol when used at this
dosage attenuated IIR injury in rats [31]. At the 4th day, parts
of the rats were sacrificed by overdose of anesthetic chloral
hydrate, and the intestinal mucous was obtained and scraped
for further determination and the intestinal morphological
changes were assessed.
Oxidative Medicine and Cellular Longevity 3
2.7. Experimental Groups. The other rats were divided into
the following groups.
(1) Sham-operated group (SHAM) (𝑛 = 6): rats pre-
treated with normal saline (10mL/kg, i.p.) were
subjected to identical surgical procedures except
for superior mesenteric artery (SMA) occlusion for
75min and were kept under anesthesia during the
experiment and were administrated with the same
volume of normal saline (1mL/kg, i.v.) as reagent
solvent control.
(2) Sole IIR group (IIR) (𝑛 = 6): rats pretreated with
normal saline (10mL/kg, i.p.) were subjected to small
intestinal ischemia by occluding SMA (75min), fol-
lowed by reperfusion (2 h) plus administration of nor-
mal saline (1mL/kg, i.v.) 5min immediately before
reperfusion.
(3) IIR + Compound 48/80 group (IIR + CP) (𝑛 = 12):
rats pretreated with normal saline (10mL/kg, i.p.)
were subjected to small intestinal ischemia by occlud-
ing SMA (75min), followed by reperfusion (2 h) plus
administration of Compound 48/80 (0.75mg/kg, i.v.)
dissolved in normal saline (1mL/kg) 5min immedi-
ately before reperfusion.
(4) NAC+ IIR group (NAC+ IIR) (𝑛 = 6): rats pretreated
with NAC (0.5 g/kg, i.p./day) dissolved in normal
saline (10mL/kg) for 3 successive days were sub-
jected to small intestinal ischemia by occluding SMA
(75min), followed by reperfusion (2 h) plus adminis-
tration of normal saline (1mL/kg, i.v.).
(5) NAC + IIR + Compound 48/80 group (NAC + IIR +
CP) (𝑛 = 6): rats pretreated with NAC (0.5 g/kg, i.p.)
were subjected to small intestinal ischemia by occlud-
ing SMA (75min), followed by reperfusion (2 h) plus
administration of Compound 48/80 (0.75mg/kg, i.v.).
(6) Propofol + IIR group (Pro + IIR) (𝑛 = 6): rats pre-
treatedwith propofol (50mg/kg, i.p./day) dissolved in
intralipid (10mL/kg) for 3 successive days were sub-
jected to small intestinal ischemia by occluding SMA
(75min), followed by reperfusion (2 h) plus adminis-
tration of normal saline (1mL/kg, i.v.).
(7) Propofol + IIR + Compound 48/80 group (Pro +
IIR + CP) (𝑛 = 6): rats pretreated with propofol
(50mg/kg, i.p.) were subjected to small intestinal
ischemia by occluding SMA (75min), followed by
reperfusion (2 h) plus administration of Compound
48/80 (0.75mg/kg, i.v.).
(8) Intralipid + IIR group (Lip + IIR) (𝑛 = 12): rats
pretreated with intralipid (50mg/kg, i.p.) (with a vol-
ume of 10mL/kg) were subjected to small intestinal
ischemia by occluding SMA (75min), followed by
reperfusion (2 h) plus administration of normal saline
(1mL/kg, i.v.).
(9) Intralipid + IIR + Compound 48/80 group (Lip +
IIR + CP) (𝑛 = 12). rats pretreated with intralipid
(50mg/kg, i.p.) were subjected to small intestinal
ischemia by occluding SMA (75min), followed by
reperfusion (2 h) plus administration of Compound
48/80 (0.75mg/kg, i.v.).
It is of notice that, with respect to the low survival rate in rats
that underwent IIR in the presence of CP, experiments were
performed on a total of 12 animals in IIR + CP and IIR + CP
+ intralipid groups. In all the experimental groups, the rats
were anesthetized by intraperitoneal injection of 10% chloral
hydrate (3.5mL/kg) after fasting for 16 h. The Compound
48/80 (Sigma, USA; 0.75mg/kg) or the same volume of
physiological saline was intravenously injected via the tail
vein at 5min before reperfusion. The doses of agents were
adjusted in accordance with our previous study [15]. During
the surgery, all the rat body temperature was maintained at
38∘C using heated pad. And 10mL/kg 37∘C normal saline
was injected subcutaneously to avoid dehydration after the
abdomen had been closed.
2.8. Collection of Intestinal Mucosa. Upon the completion of
the abovementioned treatments and experiments, the rats
were anesthetized and then euthanized. The whole small
intestine was removed carefully, and a segment of 1.0 cm
intestine (located at 10 cm away from the terminal ileum)
was cut and fixed in 10% formaldehyde and then embedded
in paraffin for section. The remaining small intestine was
washed thoroughly with 0∘C normal saline and then opened
longitudinally to expose the intestinal epithelium, after being
rinsed completely with 0∘C normal saline and dried with
suction paper. The mucosal layer was harvested by gentle
scraping of the epitheliumwith a glass slidewith a plate on the
ice and then was stored at −70∘C for further measurements.
2.9. Intestinal Histology. Five 𝜇m thick sections were pre-
pared from paraffin-embedded intestine tissue; the segment
of small intestine was stained with hematoxylin-eosin. And
the damage of intestinal mucosa was evaluated by two histol-
ogists blinded to the experiment according to Chiu’s standard
[32]: Grade 0, normal mucosa; Grade 1, development of
subepithelial Gruenhagen’s space at the tip of villus; Grade 2,
extension of the space with moderate epithelial lifting; Grade
3, massive epithelial lifting with a few denuded villi; Grade 4,
denuded villi with exposed capillaries;Grade 5, disintegration
of the lamina propria, ulceration, and hemorrhage.
2.10. Detection of 15-F
2𝑡
-Isoprostane Content in the Small
Intestinal Mucosa. Small intestinal mucosa was homoge-
nized with normal saline. The tissue content of free 15-F
2t-
isoprostane, an index of in vivo oxidative stress-induced lipid
peroxidation, was measured using commercial immunoassay
kits (CaymanChemical, AnnArbor,MI) aswedescribed [33].
2.11. Assay of Superoxide Dismutase (SOD) Activity and
Hydrogen Peroxide Content in Small Intestinal Mucosa. Small
intestinal mucosa was made into a homogenate with nor-
mal saline, frozen at −20∘C for 5min, and centrifuged for
15min at 4000 r/min. Supernatants were transferred into
fresh tubes for evaluation of SOD activity and hydrogen
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peroxide content. SOD activity and hydrogen peroxide con-
tent were assessed by SOD and hydrogen peroxide detection
kits according to the manufacturer’s instructions (Jiancheng
Bioengineering Ltd, Nanjing, China). Presented data were
normalized to tissue weight.
2.12. Measurement of 𝛽-Hexosaminidase Level in Serum. 𝛽-
hexosaminidase level in the serum was determined using
modification of a previously described method [34]. Briefly,
50𝜇L of serum was incubated with 50 𝜇L of 1mM p-
nitrophenyl-N-acetyl-𝛽-D-glucosaminide dissolved in 0.1M
citrate buffer (pH 5) in a 96-well plate at 37∘C for 1 h. The
reaction was terminated with 200 𝜇L/well of 0.1M carbonate
buffer (pH 10.5). The absorbance at 405 nm was measured
using a Microplate reader.
2.13. Western Blotting. Intestinal mucosa samples were
homogenized with lysis buffer for 30 seconds in a mortar and
pestle with liquid nitrogen. Homogenates were centrifuged at
13000 rpm for 10min at 4∘Cand the supernatantwas collected
as the source of protein sample. The proteins were processed
with standardmethods forWestern blot analysis as described
[10]. Rat monoclonal anti-tryptase antibody, rat monoclonal
anti-gp91phox and anti-p47phox antibodies, rat monoclonal
anit-P-selectin and anti-ICAM-1 antibodies, and 𝛼-tubulin
antibody were obtained from Santa Cruz (Santa Cruz, CA,
USA). The secondary antibody conjugated to horseradish
peroxidase was diluted at 1 : 2,000 (Santa Cruz, USA).
Immunoblots were incubated with an enhanced chemilumi-
nescence detection system (KeyGen Biotech, China) and the
densitometry analysis was performed using Quantity One
software.
2.14. Determination of IL-6 Production in Small Intestinal
Mucosa by Enzyme Immunoassay. Intestinal mucosa tissues
were made into homogenates with frozen normal saline and
spun at 4000 r/min for 15 minutes. Supernatants were then
transferred into fresh tubes for detection of IL-6 contents.
Briefly, intestinal protein was measured by BCA Protein
Assay Kit provided by KenGen Biotech Company, Nanjing,
China, and the protein contents were expressed as g/L. The
levels of IL-6 were measured using commercial ELISA kits
following manufacturer’s instructions (R&D systems Inc,
USA). The absorbance was read at 450 nm by a Biokinetics
microplate reader Model EL340 (Biotek Instruments, USA),
and the results were expressed as ng/L; then the final levels of
IL-6 in the intestine were calculated as ng/g protein.
2.15. Determination of Myeloperoxidase (MPO) Activity in
Small Intestinal Mucosa. Myeloperoxidase (MPO) activity
was determined with the O-dianisidine method [35], using
a MPO detection kit (Nanjing Jiancheng Bioengineering
Institute) as we described [36]. MPO activity was defined
as the quantity of enzyme degrading 1𝜇mol of peroxide per
minute at 37∘C and was expressed in units per gram weight
of wet tissue.
2.16. Statistical Analysis. The data (except for the survival
rates) were expressed as Mean ± SEM. All biochemical
assays were performed in duplicate. Analysis of variance was
performedusingGraphpadPrism software.One-way analysis
of variance was used for multiple comparisons, followed by
Bonferroni’s Student’s 𝑡-test for unpaired values. The survival
rate was expressed as the percentage of live animals, and the
Mantel Cox log rank test was used to determine differences
between groups. Differences were considered significant
when 𝑃 values were less than 0.05.
3. Results
3.1. Oxidative Stress but Not LPS-Induced RBL-2H3 Cell
Degranulation Can Be Reversed by NAC and Propofol Pre-
treatments. Bacterial translocation and oxidative stress are
the two characterizations of small IIR [37], and our previous
study showed that mast cell (MC) degranulation could
exacerbate the injury [14]. Therefore, in the current study,
we initially sought to explore whether bacteria and oxidative
stress can induce MC degranulation. As shown in Figure 1,
exposure of the RBL-2H3 to different concentrations of
LPS for 1 or 4 h did not cause significant changes in the
release of 𝛽-hexosaminidase activities as compared with the
control group (Figure 1(a)) whereasMC activator Compound
48/80 significantly increased the released 𝛽-hexosaminidase
activities as compared with the control group (Figure 1(b)).
This result indicates that LPS per se has no effects on MC
degranulation at least in this experimental setting. However,
treatment of RBL-2H3 cell with H
2
O
2
dose-dependently
increased the activity of the released 𝛽-hexosaminidase
(Figure 1(c)). Pretreatments with NAC, a scavenger of oxy-
gen radicals, abolished H
2
O
2
mediated elevations of the
released 𝛽-hexosaminidase activities (Figure 1(d)). Similarly,
pretreatment with propofol, but not intralipid (propofol
solvent), abrogated the enhancements of the released 𝛽-
hexosaminidase activities induced by H
2
O
2
(Figure 1(e)),
indicating that oxidative stress contributes to MC degran-
ulation and propofol inhibits MC degranulation via its
antioxidant property.
3.2. TryptaseContributed to Small Intestinal Epithelium Injury.
Tryptase, the unique mediator released from MC degranu-
lation [38], plays a critical role in the IIR mediated acute
lung injury in vivo [15]. Therefore, we sought to define the
direct role of tryptase in the small intestinal epithelium injury
in vitro. A small intestinal epithelial cell line IEC-6 was
employed and exposed to different concentrations of tryptase.
The results showed that tryptase could directly cause IEC-6
injury in a dose-dependent manner manifested as dramatic
increases in LDH activities and concomitant reductions in
cell viability as compared with the control group (Figures 1(f)
and 1(g)).
3.3. NAC, Propofol, and Intralipid PretreatmentsDidNotAffect
Small Intestinal Structure before IIR. First, we sought to assess
if pretreatment of rats with NAC, propofol, or intralipid may
cause significant intestinal injury. At the dosages used, neither
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Figure 1: Effects of LPS, Compound 48/80, and hydrogen peroxide (H
2
O
2
) on the degranulation of RBL-2H3 cells with or without NAC or
propofol treatment. (a) 𝛽-Hexosaminidase release after LPS treatment for 1 h or 4 h, (b) 𝛽-hexosaminidase release after Compound 48/80
stimulation for 1 h, and (c) 𝛽-hexosaminidase release after H
2
O
2
treatment for 1 h. (d) and (e) quantified the degranulation of RBL-2H3 cells,
pretreated with NAC or propofol for 12 h, induced by H
2
O
2
stimulation for 1 h, respectively. (f) Cell viability of IEC-6 cells treated with
tryptase for 12 h. Results were expressed as percentage of control group; error bars represented the standard error of the mean. (g) Lactate
dehydrogenase (LDH) activity of IEC-6 cells treated with tryptase for 2 h. Results were expressed as Mean ± SEM. ∗𝑃 < 0.05 versus control
group, #𝑃 < 0.05 versus H2O2 500 𝜇M group,
$
𝑃 < 0.05 versus propofol 0.5𝜇g/mL group.
NACnor propofol or intralipid caused any challenges to small
intestinal structure as compared to that in rats treated with
normal saline (NS). As shown in Figure 2, all the layers of
intestine were normal in all the groups and there was no
significant difference among groups in terms of injury score
(Figure 2(d)).
3.4. NAC and Propofol but Not Intralipid Pretreatment Altered
Intestinal Oxidant and Antioxidant Levels before IIR. NAC
andpropofol arewell known for their antioxidative properties
[10, 39]. As shown in Figure 3, NAC and propofol simi-
larly attenuated oxidant level as demonstrated by significant
decreases in 15-F
2t-isoprostane (Figure 3(a)) contents and
increases in SOD activities (Figure 3(b)) in small intestinal
mucosa as comparedwithNS treated group. In addition,NAC
and propofol pretreatment led to significant reductions in
protein expressions of gp91phox and p47phox, the important
components of NADPH enzymes, in small intestinal mucosa
compared with NS treated group before IIR (Figures 3(c)–
3(e)). By contrast, intralipid showed comparative results to
NS treated group.Thedata indicated that propofol, at the dose
used, confers similar antioxidant effects to that of NAC.
3.5. NAC, Propofol, and Intralipid Pretreatments Did Not Acti-
vate Mast Cell before IIR. Trypatse and 𝛽-hexosaminidase
are specific markers for the assessment of mast cells degran-
ulation [40]. As shown in Figures 3(f) and 3(g), NAC,
propofol, or intralipid alone had no significant effect on
mast cell degranulation.There were no significant differences
in tryptase protein expressions in small intestinal mucosa
and 𝛽-hexosaminidase levels among all pretreated groups
before IIR.The findings from the current study indicated that
NACandpropofol pretreatments can substantially ameliorate
superoxide productions without affecting mast cell and small
intestine morphology under normal condition.
3.6. NACandPropofol Improved Reduction of Survival Rates in
Rats Challenged to IIR through InhibitingMast Cell Activation.
We, next, sought to investigate the effects of NAC and propo-
fol in combating IIR and inhibiting mast cell in the process
of IIR injury. As illustrated in Figure 4(a), activation of mast
cell by Compound 48/80 resulted in significant decreases in
2 h survival rates after the clamp releasing as compared with
sole IIR group. By contrast, NAC and propofol pretreatments
showed similar promising benefits in reducing mast cell
degranulation mediated injury during 2 h reperfusion period
evidenced as increased postischemic 2 h survival rates to
100% (Figure 4(b)). Intralipid did not attenuate Compound
48/80 mediated exacerbation of postischemic survival rate
in rats subjected to IIR (Figure 4(c)). These data suggested
that oxidative stress is a major mechanism whereby mast cell
degranulation exacerbated IIR injury.
3.7. NAC and Propofol Attenuated Small Intestinal Injury in
Rats Undergoing IIR through Inhibiting Mast Cell Activation.
After 2 h reperfusion, the sections of small intestine were
evaluated by HE staining; IIR induced severe damage to
small intestine. As depicted in Figures 4(d) and 4(e), multiple
erosions and bleeding were observed in IIR group, while
Compound 48/80 further aggravated IIR injury manifested
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Figure 2: Morphological changes of intestine under light microscope in rats treated with NAC, propofol, or intralipid. ((a)–(d))
Representative images of rats treated with normal saline (NS), NAC (0.5 g/kg, i.p.), propofol (50mg/kg, i.p.), and intralipid (50mg/kg, i.p.)
prior to ischemia reperfusion (HE staining, ×200). (e) quantified the intestine histological scores in normal saline pretreated group (NS),
NAC pretreated group (NAC), propofol pretreated group (Pro), and intralipid pretreated group (Lip). Results are expressed as Mean ± SEM.
𝑛 = 3 per group.
as moremultiple erosions and bleedings andmore inflamma-
tory cell sequestrations seen in the IIR + CP group, whereas
the villus and glands were normal and no inflammatory
cell infiltration was observed in mucosal epithelial layer
in Sham-operated group. NAC and propofol similarly and
significantly reduced the injuries in small intestine and only
slight edema of mucosa villus and infiltration of few necrotic
epithelial inflammatory cells were found in mucosa epithelial
layer. Moreover, NAC and propofol pretreatments blocked
Compound 48/80 induced exacerbation in small intestinal
morphology changes after 2 h reperfusion. In contrast, pre-
treatment with intralipid could not attenuate IIR and Com-
pound 48/80 induced injury. Consistent with morphological
changes, Chiu’s scores markedly increased in IIR group as
compared with Sham-operated group while treatment with
mast cell degranulator Compound 48/80 after ischemia led to
further increases inChiu’s scores.NACandpropofol similarly
dramatically lowered Chiu’s scores and significantly limited
the changes induced by Compound 48/80 (𝑃 < 0.05, NAC +
IIR + CP or propofol + IIR + CP versus IIR + CP group). Of
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Figure 3: Changes of 15-F
2t-isoprostane contents, SOD activities, p47
phox and gp91phox protein expressions in intestine mucosa, and intestinal
tryptase protein expression, and serum 𝛽-hexosaminidase levels in rats treated with NAC, propofol, and intralipid. (a) 15-F
2t-isoprostane
contents, (b) SOD activities, ((c)–(e)) intestinal p47phox and gp91phox protein expressions, (f) tryptase protein expression, and (g) 𝛽-
hexosaminidase levels in normal saline pretreated group (NS), NAC pretreated group (NAC), propofol pretreated group (Pro), and intralipid
pretreated group (Lip) (𝑛 = 3). Results are expressed as Mean ± SEM. ∗𝑃 < 0.05 versus NS.
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Figure 4: Survival rates and morphological changes of intestine and intestinal histological score under light microscope after IIR. SHAM
group (Sham-operated group), IIR group (75min intestinal ischemia and 2 h reperfusion), and IIR + CP group (IIR group + Compound
48/80 1mg/kg) in the absence or presence of NAC (0.5 g/kg) or propofol (50mg/kg) or intralipid (50mg/kg). ((a)–(c)) Survival rats in rats
subjected to IIR with or without NAC, propofol, or intralipid pretreatment. Results are expressed as percentage of live animals, 𝑛 = 6 per
group, whereas 𝑛 = 12 in IIR + CP group and IIR + CP + intralipid group. (d) Representative images of HE staining (×200). Black arrow:
lamina propria villus shedding. Red arrow: engorgement of capillary vessel. White arrow: top villus shedding. (e) quantified the intestine
histological scores. Results are expressed as Mean ± SEM. 𝑛 = 6 per group, whereas 𝑛 = 4 in IIR + CP group. ∗𝑃 < 0.05 versus SHAM group,
#
𝑃 < 0.05 versus IIR group, $𝑃 < 0.05 versus IIR + CP group, &𝑃 < 0.05 versus IIR with NAC pretreated group, △𝑃 < 0.05 versus IIR with
propofol pretreated group, and 󳵳𝑃 < 0.05 versus IIR with intralipid pretreated group.
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note, there were no differences in Chiu’s scores between IIR
and intralipid pretreated groups.
3.8. NAC and Propofol Reduced Oxidative Stress in Small
Intestine in Rats Undergoing IIR through Inhibiting Mast Cell
Activation. Ischemia reperfusion injury is characterized by
upregulation of ROS [10]. In linewith previous results [16], we
observed that 75min ischemia followed by 2 h reperfusion led
to substantial enhancements in 15-F
2t-isoprostane contents
in small intestinal mucosa and marked reductions in SOD
activities as compared with Sham-operated group (Figures
5(a) and 5(b)). Meanwhile, IIR also caused great increases in
gp91phox and p47phox protein expressionwhen comparedwith
Sham-operated group. Moreover, Compound 48/80 further
aggravated the changes of oxidative stress induced by IIR
(𝑃 < 0.05 IIR + CP versus IIR). Not surprisingly, propofol
and NAC similarly attenuated IIR mediated oxidative stress
evidenced as downregulation of 15-F
2t-isoprostane contents
and gp91phox and p47phox protein expression and upregula-
tion of SOD activities in propofol and NAC treated groups as
compared with group IIR. Furthermore, propofol and NAC
pretreatments also limited the further increases of oxidative
stress induced by Compound 48/80. As expected, intralipid
did not show any antioxidative properties as the markers of
oxidative stress measured were comparable between group
IIR and group intralipid + IIR. Intralipid had no protective
effect against Compound 48/80 induced upregulation of
oxidative stress.
3.9. NAC and Propofol Attenuated Inflammation in Small
Intestine in Rats Undergoing IIR through Inhibiting Mast Cell
Activation. Interleukin 6 (IL-6) is one of the inflammatory
cytokines that has been demonstrated to be implicated in
the pathogenesis of IIR injury [41]. In the present study,
we observed that IL-6 levels in small intestinal mucosa
in group IIR were significantly increased as compared to
that in the Sham-operated group (Figure 5(e)). Moreover,
administration with Compound 48/80 further resulted in
dramatic enhancements in IL-6 levels in group IIR + CP
(𝑃 < 0.05 versus group IIR). Pretreatments with propofol and
NAC not only similarly abrogated the increases in IL-6 levels,
but also block the enhancements in IL-6 levels resulting from
IIR in the presence of the MC activator Compound 48/80
(Figure 5(e)).
3.10. NAC and Propofol Inhibited Neutrophil Rolling in Small
Intestine in Rats Undergoing IIR through Inhibiting Mast Cell
Activation. IIR injury is also characterized by neutrophil
sequestrating into the inflamed tissues [42]. Consistent with
previous results [42], we also found that IIR led to substan-
tial increases in MPO activities (Figure 5(f)) and ICAM-1
(Figure 5(g)) and P-selectin (Figure 5(h)) protein expressions
as compared with Sham-operated group; moreover, Com-
pound 48/80 resulted in further increases in MPO activities
and P-selectin protein expression in group IIR + CP than that
in group IIR. Administrations with propofol andNAC signif-
icantly inhibited neutrophil infiltration/activation evidenced
as downregulation of MPO activities and P-selectin protein
expression caused by IIR. Furthermore, propofol and NAC
also blocked Compound 48/80 mediated exacerbation of IIR
induced neutrophil infiltration.
3.11. NAC and Propofol Reduced Mast Cell Degranulation in
Small Intestine in Rats Undergoing IIR. Mast cell releases a
number ofmediators that contribute to the aggravation of IIR
injury, and there are many factors that can induce mast cell
degranulation during IIR. Tryptase and 𝛽-hexosaminidase
are the unique markers released from mast cell and their
increased release can be recognized as mast cell degranula-
tion. As shown in Figure 6, after 2 h reperfusion, we found
that tryptase protein expression and 𝛽-hexosaminidase level
were greatly increased in group IIR as compared with Sham-
operated group, and Compound 48/80 resulted in further
mast cell degranulation evidenced as dramatic increases
in tryptase protein expression and 𝛽-hexosaminidase level
observed in group IIR + CP relative to that in group IIR.
Of note, propofol and NAC similarly inhibited mast cell
degranulation by downregulating tryptase protein expression
and 𝛽-hexosaminidase level triggered by IIR and Compound
48/80. Collectively, the findings from the current study indi-
cated that oxidative stress mediated mast cell degranulation
aggravated IIR injury and propofol through its antioxidative
properties protects against IIR by stabilizing mast cell.
4. Discussion
We have shown in the current study that increased ROS
during IIR exacerbated IIR injury primarily via activating
mast cells evidenced as concomitant increases of postis-
chemic 15-F
2t-isoprostane and elevations in tryptase and 𝛽-
hexosaminidase and increases in intestinal injury score, lead-
ing to significantly reduced postischemic survival. Further,
we showed that activation of intestinal NADPH oxidase is a
major source of postischemic ROS production. Antioxidant
NAC and propofol inhibited postischemic intestinal NADPH
oxidase activation by reducing gp91phox and p47phox protein
overexpression and reduced ROS and the subsequent mast
cell activation in vivo and in vitro, which may represent the
major mechanism whereby propofol attenuates IIR injury
and enhances postischemic survival.
Mast cell (MC), which contains a diverse range of medi-
ators, resides throughout gastrointestinal tract and is also
known as intestinal mucosal mast cell (IMMC). Despite the
fact thatMCmay function as host defense to prevent bacterial
invasion [43], enhancedMC activation may contribute to the
development of a variety of disorders including IIR injury
by releasing histamine, tryptase, TNF-𝛼, and other factors. It
should be noted that MC is the main source of TNF-𝛼 in the
tract [44]. Ramos et al. reported that mast cell degranulation
plays a significant role in the development of sepsis by reg-
ulating cell death, which resulted in multiorgan dysfunction
[45]. Consistent with the previous studies showing that stabi-
lizing MC from degranulation would be one of the potential
strategies in combating IIR injury [14], our current study
further revealed that increased oxidative stress during IIR
plays an important role in mast cell activation/degranulation
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Figure 5: Changes of SOD activities, 15-F
2t-isoprostane contents, p47
phox protein expression, gp91phox, P-selectin, and ICAM-1 protein
expressions, IL-6 levels, and MPO activities in intestine mucosa after IIR injury. SHAM group (Sham-operated group), IIR group (75min
intestinal ischemia and 2 h reperfusion), and IIR + CP group (IIR group + Compound 48/80 1mg/kg) in the absence or presence of NAC
(0.5 g/kg), propofol (50mg/kg), intralipid (50mg/kg). (a) SOD activities, (b) 15-F
2t-isoprostane contents in intestine (𝑛 = 6, except 𝑛 = 4 in
IIR + CP group). ((c) and (d)) p47phox and gp91phox protein expressions, respectively (𝑛 = 3), ((e) and (f)) IL-6 levels and MPO activities in
intestinal mucosa (𝑛 = 6, except 𝑛 = 4 in IIR + CP group). ((g) and (h)) ICAM-1 and P-selectin protein expressions, respectively (𝑛 = 3).
Results are expressed as Mean ± SEM. ∗𝑃 < 0.05 versus SHAM group, #𝑃 < 0.05 versus IIR group, $𝑃 < 0.05 versus IIR + CP group,
&
𝑃 < 0.05 versus IIR with NAC pretreated group, △𝑃 < 0.05 versus IIR with propofol pretreated group, and 󳵳𝑃 < 0.05 versus IIR with
intralipid pretreated group.
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Figure 6: Changes of intestinal tryptase protein expression and serum𝛽-hexosaminidase levels after IIR injury. SHAMgroup (Sham-operated
group), IIR group (75min intestinal ischemia and 2 h reperfusion), and IIR + CP group (IIR group + Compound 48/80 1mg/kg) in the
absence or presence of NAC (0.5 g/kg), propofol (50mg/kg), intralipid (50mg/kg). (a) Intestinal tryptase protein expression (𝑛 = 3). (b)
𝛽-hexosaminidase levels in serum (𝑛 = 6, except 𝑛 = 4 in IIR + CP group). Results are expressed as Mean ± SEM. ∗𝑃 < 0.05 versus SHAM
group, #𝑃 < 0.05 versus IIR group, $𝑃 < 0.05 versus IIR + CP group, &𝑃 < 0.05 versus IIR with NAC pretreated group, △𝑃 < 0.05 versus IIR
with propofol pretreated group, and 󳵳𝑃 < 0.05 versus IIR with intralipid pretreated group.
evidenced as enhancements in tryptase protein expression
and 𝛽-hexosaminidase levels, which causes or exacerbates
IIR injury. This notion is further supported by the fact that
activating mast cell by Compound 48/80 further aggravated
IIR injury and tryptase directly damaged small intestinal
epithelium evidenced by the reduced cell viability and the
enhanced LDH activity in vitro. The data from the current
study further proved that mast cell activation plays a central
role in exacerbating IIR injury, although the mechanism
governingmast cell activation during IIR is yet to be explored.
Mast cell can be activated by several distinct mecha-
nisms; in addition to IgE/Fc𝜀, the classical signal pathway
of activation, there is a growing body of evidence to sug-
gest that nonimmunological stimuli such as trauma and
physical stress also contribute to mast cell activation [46].
Yoshimaru and colleagues demonstrated that silver mediated
mast cell activation by upregulation of NADPH oxidase
mediated ROS production [18]. Additionally, Collaco et al.
found that superoxide production contributes to mast cell
degranulation, and inhibiting ROS can stabilize mast cell in
vitro [12]. Moreover, our previous study in a rat model of
IIR revealed significant increase of mast cell activation with
concomitant elevations in ROS [16]. These results provided
us sound rationale to speculate that there exists a linkage
between mast cell activation and superoxide production.
Our current study extended findings of previous studies
[16] by showing that NADPH oxidase is overexpressed
during IIR which contributed to increased oxidative stress
and MC activation, leading to exacerbation of IIR injury.
Further, using antioxidant N-acetylcysteine (NAC), which
has been shown to prevent myocardial NADPH oxidase
overexpression in diabetes [47, 48] and attenuate myocardial
ischemia reperfusion injury [10], we found that, in in vivo
model of IIR, pretreatment of rats with NAC not only
attenuatedNADPHoxidase overexpression and reducedROS
production, but concomitantly reduced MC activation and
consequently attenuated IIR injury and increased survival
rate. We also found that NAC reversed the oxidative stress
mediated mast cell degranulation in vitro. The results from
the current study indicated that oxidative stress subsequent
to NADPH oxidase overexpression during IIR plays a critical
role in mast cell activation, which in turn led to a deleterious
injury. Of note, in the current study, mast cell activation by
CP also induced oxidative stress manifested as increased 15-
F
2t-isoprostane and reduced SOD, associated with increased
p47phox and gp91phox protein expression in IIR + CP group
compared to IIR group (Figures 5(a)–5(d)).This is consistent
with study from Collaco et al. showing that sodium sulfite
activated mast cell degranulation and subsequently increased
intercellular oxidative stress in RBL-2H3 cells [12]. These
indicate that mast cell activation per se induces oxidative
stress.
Excessive production of ROS by NADPH oxidase is
generally considered to be involved in the pathogenesis of
inflamed tissues [49], including ischemic tissues. There are
a number of NADPH homologs presented in many diverse
organs, such as Nox1, Nox2 (also named as gp91phox), and
Nox3-4 [50]. It is important to appreciate that Nox2 is pre-
dominantly expressed within epithelial cells. In addition to
ROS scavenger, NAC also inhibits NADPH oxidase activities;
our previous results showed that pretreatment of diabetic
rats withNAC attenuated cardiac ischemia reperfusion injury
by downregulating NADPH subunits p67phox and p22phox
expression and reducing oxidative stress [48]. Inoue et al.
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have demonstrated that blockade of ROS generation by
NADPH oxidase inhibition can limit mast cell degranulation
[51]. Guan et al. demonstrated that intracellular NADPH
concentration in villus tip cells in intestine was significantly
rapidly increased even after short-term ischemia [52]. In
the current study, we also found that elevations of gp91phox
and p47phox protein expression are the prominent features of
IIR. Furthermore, precondition of IIR-rats with antioxidant
NAC or propofol not only significantly reduced gp91phox and
p47phox protein expression, but also played a significant role
in stabilizing mast cell.
Propofol is a short-acting, intravenously administered
hypnotic agent. In addition to its sedation/hypnotic prop-
erties, propofol displays protective effects in many organs
subjected to ischemia reperfusion injury by inhibiting oxida-
tive cellular damage [53, 54]. Hama-Tomioka et al. recently
reported that propofol can block superoxide production
originated from NADPH oxidase in vitro [55]. Although, as
described previously, a single intraperitoneal injection of 50
or 100mg/kg propofol could significantly attenuate IIR injury
in acute rat models [31], propofol is the most commonly
used agent overall during short-term and intermediate-
length sedation in ICU [56]; thus, in the current study, we
explored propofol pretreatment for three successional days
and incorporated the investigation of postischemic mortality
in addition to observing its effect on IIR injury. To our
knowledge, our study is the first to show that propofol
pretreatment given at a sedative dosage significantly inhibited
the overexpression of NADPH oxidase and reduced oxidative
mediated MC action during IIR or in vitro and reduced IIR
injury and subsequently enhanced postischemic mortality in
rats.
IIR injury is also characterized by uncontrollable inflam-
mation and neutrophils sequestration in inflamed tissues.
Migration of neutrophils to injurious site is mediated by
selectins and intercellular adhesion molecules (ICAMs) by
the activated endothelium [57]. Compton et al. reviewed that
tryptase released from mast cell degranulation can attract
leukocytes infiltrate and migrate to ischemic tissues [58].
And treatment of rats with mast cell stabilizer cromolyn
sodium has been shown to greatly reduce the expressions of
ICAM-1 in the lungs in pancreatitis-associated lung injury
and decreased IL-6 release [59]. These findings point to the
importance of mast cell degranulation through increased
release of proinflammatory mediator in inducing neutrophil
migration to inflamed tissues. In the present study, we found
that, during IIR, mast cell degranulation resulted in more
neutrophils infiltration into small intestine evidenced as
significant increases in MPO activities and ICAM-1 and P-
selectin protein expressions and that propofol and NAC sim-
ilarly blocked the alterations induced by IIR and prevented
MC stimulator Compound 48/80 mediated exacerbation of
IIR injury. Our finding that propofol can inhibit intestinal
MC activation during IIR and reduce tissue neutrophils
infiltration as well as the subsequent systemic inflammation
may have potential clinical importance given that IIR occurs
often in patient who underwent major surgeries such as
cardiac surgery with cardiopulmonary bypass [60] and is
a challenging and life-threatening clinical problem.The delay
in diagnosis and treatment of IIR injury contributes to the
continued high in-hospital mortality rate [61]. Preventive
administration of propofol may be a promising approach in
attenuating postoperative intestinal ischemia and mortality.
In a summary, we have shown that mast cell activation,
through increased release of mediators, contributed to dele-
terious injury induced by IIR and that oxidative stress plays
a central role in mast cell activation. Propofol, similar to the
antioxidant NAC, inhibited ROS mediated mast cell activa-
tion and attenuated IIR injury and enhanced postischemic
mortality. Propofol mediated reduction of oxidative stress
and MC activation during IIR is achieved at least in part
through attenuating IIR induced NADPH oxidase overex-
pression, while the underlying mechanism merits further
study. Mast cell activation contributes to and exacerbates
small intestinal ischemia reperfusion injury.
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